Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma

Paolo Corradini, Marco Ladetto, Monica Astolfi, Claudia Voena, Corrado Tarella, Andrea Bacigalupo, Alessandro Pileri

Research output: Contribution to journalArticlepeer-review

Abstract

Mantle-cell lymphoma (MCL) is a B-cell tumour with a usually poor prognosis, characterized by the proliferation of small cleaved lymphocytes with a diffuse growth pattern. We report a polymerase chain reaction-based analysis of minimal residual disease in a patient who achieved complete remission after allogeneic blood cell transplantation (BCT). Rearrangement of the immunoglobulin heavy-chain genes was used to generate a lymphoma-specific molecular marker. Lymphoma cells were not detectable in a bone marrow sample collected 12 months after BCT. Our findings suggest that allogeneic BCT may offer a curative approach to MCL.

Original languageEnglish
Pages (from-to)376-378
Number of pages3
JournalBritish Journal of Haematology
Volume94
Issue number2
Publication statusPublished - 1996

Keywords

  • allogeneic transplantation
  • IgH genes
  • mantle-cell lymphoma
  • minimal residual disease
  • polymerase chain reaction

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma'. Together they form a unique fingerprint.

Cite this